Fisher Asset Management LLC Raises Stock Position in Halozyme Therapeutics, Inc. $HALO

Fisher Asset Management LLC boosted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 467,852 shares of the biopharmaceutical company’s stock after purchasing an additional 56,960 shares during the period. Fisher Asset Management LLC’s holdings in Halozyme Therapeutics were worth $31,486,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HALO. Root Financial Partners LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $25,000. Larson Financial Group LLC raised its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares during the period. Clearstead Advisors LLC raised its stake in Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the period. Penserra Capital Management LLC purchased a new position in Halozyme Therapeutics during the third quarter worth about $52,000. Finally, Wexford Capital LP purchased a new position in Halozyme Therapeutics during the third quarter worth about $70,000. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Trading Up 0.6%

Shares of HALO stock opened at $68.72 on Wednesday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm has a market cap of $8.15 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. The company has a 50-day moving average of $65.94 and a two-hundred day moving average of $68.77. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm posted $1.11 earnings per share. Halozyme Therapeutics’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, analysts predict that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Insider Activity

In other news, COO Cortney Caudill sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $67.80, for a total value of $1,356,000.00. Following the completion of the transaction, the chief operating officer owned 14,366 shares of the company’s stock, valued at approximately $974,014.80. This trade represents a 58.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the transaction, the director directly owned 38,498 shares of the company’s stock, valued at approximately $2,443,853.04. The trade was a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 120,482 shares of company stock valued at $8,200,842. 2.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Benchmark lifted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Wells Fargo & Company increased their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.